Business Context and Reporting Period
Company: Innovative Eyewear, Inc. (Ticker: LUCY)
Filing Type: Form 8-K (Current Report)
Date of Report: April 11, 2025
Event Date: April 11, 2025 (Agreement); April 14, 2025 (Closing)
Context: The Company entered into inducement letter agreements with holders of existing warrants to facilitate the exercise of those warrants at a reduced price in exchange for the issuance of new warrants.
Key Financial Metrics and Transaction Details
- Gross Proceeds: Approximately $1.8 million (prior to deducting placement agent fees and offering expenses).
- Use of Proceeds: Working capital and general corporate purposes.
- Existing Warrants Exercised: 595,188 shares total (121,500 at original $5.00 price; 473,688 at original $9.50 price).
- Reduced Exercise Price: $2.60 per share for the Existing Warrants.
- New Warrants Issued:
- Series G: 218,646 shares; Exercise price $2.60; Term 5.5 years.
- Series H: 1,724,814 shares; Exercise price $2.60; Term 18 months.
- Cost to Holders: $0.125 per new warrant.
- Placement Agent Fees (H.C. Wainwright & Co., LLC):
- Cash Fee: 7.5% of gross proceeds.
- Management Fee: 1.0% of gross proceeds.
- Accountable Expenses: $50,000.
- Non-accountable Expenses: $25,000.
- Clearing Expenses: $15,950.
- PA Warrants: 44,639 shares; Exercise price $3.25; Term 5.5 years.
Note: This filing does not provide revenue, profit, cash flow, margin, debt, or liquidity metrics for the Company's operations.
Material Changes and Agreements
- Warrant Inducement: Holders agreed to exercise existing warrants at a significantly reduced price ($2.60) compared to original strike prices ($5.00 and $9.50) in exchange for new warrants.
- Registration Rights: The Company agreed to file a resale registration statement for the new warrant shares within 30 calendar days and use commercially reasonable efforts to have it declared effective within 60 days (or 90 days if a full review is required).
- Lock-up Provisions:
- No issuance of Common Stock or equivalents for 30 calendar days after closing.
- No Variable Rate Transactions for one year after closing.
Outlook, Risks, and Contingencies
- Regulatory Risk: The transaction relies on the timely effectiveness of the Resale Registration Statement. Delays in SEC review could impact the liquidity of the new warrant shares.
- Dilution: The issuance of 1,943,460 new warrant shares (Series G and H) plus 44,639 PA Warrants represents significant potential dilution to existing shareholders upon exercise.
- Unregistered Securities: The new warrants and PA warrants were issued without registration under Section 4(a)(2) and Rule 506 of the Securities Act, limiting their immediate resale.
- Management Commentary: The filing states the proceeds will be used for working capital, indicating a need for immediate liquidity.
Investor Verification Checklist
- Verify the exact net proceeds after deducting the 8.5% total cash fees and fixed expenses from the $1.8 million gross.
- Confirm the current share count to assess the immediate dilution impact of the 595,188 shares issued upon exercise of existing warrants.
- Review the Company's cash position to determine if the $1.8 million infusion is sufficient for stated working capital needs.
- Monitor the status of the Resale Registration Statement (Form S-1) to ensure it becomes effective within the 60-90 day window.
- Check for any subsequent filings regarding the "Variable Rate Transaction" restriction to ensure compliance.